Top 50 Drugs with Expiring Patents and Litigation Opportunities
Given below is the list of top 50 drugs whose majority of patents have expired and whose remaining patents present a potential opportunity to get challenged. The Drug Strength Score given below is calculated by averaging the scores of its respective patents, which are based on a mathematical assessment of various patent characteristics and its legal history. The patents' scores are calculated based on several parameters including - forward citations of the patent, patent's remaining life, number of applications blocked by it, number of PTAB proceedings on it, patent's global coverage in terms of its family members and oppositions won by the patent in European Patent Office.
*The scores shown are based on mathematical calculations using various publicly available data points and do not classify patents as "weak" or "strong" in a legal context. They are intended solely as an informational tool to provide insights and should not be considered as legal advice.
1. VIVITROL
Vivitrol is a brand drug owned by Alkermes Inc. It is Used for treating alcohol dependence. Vivitrol's 18 out of 19 patents have already expired. The remaining 1 active patent is -
1. US7919499 patent titled as " Naltrexone long acting formulations and methods of use " took more than 6 years to get granted. It has 24 family members and is forward cited by 10 patents. This patent has never blocked any other patent application. There have been 1 PTAB proceedings filed against this patent. None of these proceedings have been terminated. This patent has remaining life of approximately 5 years and 2 months.
Based on the patent analysis, the drug's overall patent strength is calculated to be -
2. FLOVENT HFA
Flovent Hfa is a brand drug owned by Glaxo Group Ltd Dba Glaxosmithkline. It is Used for treating respiratory disorders such as asthma through inhalation of a pharmaceutical formulation. Flovent Hfa's 19 out of 20 patents have already expired. The remaining 1 active patent is -
1. US7500444 patent titled as " Actuation indicator for a dispensing device " took more than 5 years to get granted. It has 35 family members and is forward cited by 71 patents. This patent has blocked 5 patent applications. There have been no PTAB proceedings filed against this patent. This patent has remaining life of approximately 2 years
Based on the patent analysis, the drug's overall patent strength is calculated to be -
3. ADVAIR HFA
Advair Hfa is a brand drug owned by Glaxo Group Ltd England Dba Glaxosmithkline. It is Used for the long-term maintenance treatment of asthma in patients 12 years of age and older. Advair Hfa's 19 out of 20 patents have already expired. The remaining 1 active patent is -
1. US7500444 patent titled as " Actuation indicator for a dispensing device " took more than 5 years to get granted. It has 35 family members and is forward cited by 71 patents. This patent has blocked 5 patent applications. There have been no PTAB proceedings filed against this patent. This patent has remaining life of approximately 2 years
Based on the patent analysis, the drug's overall patent strength is calculated to be -
4. VENTOLIN HFA
Ventolin Hfa is a brand drug owned by Glaxosmithkline Intellectual Property Ltd England. It is Used for managing bronchospasm in adults and children with reversible obstructive airways disease and preventing exercise-induced bronchospasm in patients 4 years and older. Ventolin Hfa's 17 out of 18 patents have already expired. The remaining 1 active patent is -
1. US7500444 patent titled as " Actuation indicator for a dispensing device " took more than 5 years to get granted. It has 35 family members and is forward cited by 71 patents. This patent has blocked 5 patent applications. There have been no PTAB proceedings filed against this patent. This patent has remaining life of approximately 2 years
Based on the patent analysis, the drug's overall patent strength is calculated to be -
5. PREZISTA
Prezista is a brand drug owned by Janssen Products Lp. It is Used for treating HIV infection in both adult and pediatric patients. Prezista's 12 out of 13 patents have already expired. The remaining 1 active patent is -
1. US7700645 patent titled as " Pseudopolymorphic forms of a HIV protease inhibitor " took almost 5 years to get granted. It has 78 family members and is forward cited by 31 patents. This patent has blocked 1 patent applications. There have been no PTAB proceedings filed against this patent. This patent has remaining life of approximately 2 years and 10 months.
Based on the patent analysis, the drug's overall patent strength is calculated to be -
6. VIBATIV
Vibativ is a brand drug owned by Cumberland Pharmaceuticals Inc. It is Used for treating bacterial infections, including staphylococcal infections. Vibativ's 10 out of 11 patents have already expired. The remaining 1 active patent is -
1. US7531623 patent titled as " Hydrochloride salts of a glycopeptide phosphonate derivative " took more than 4 years to get granted. It has 41 family members and is forward cited by 10 patents. This patent has never blocked any other patent application. There have been no PTAB proceedings filed against this patent. This patent has remaining life of approximately 2 years and 4 months.
Based on the patent analysis, the drug's overall patent strength is calculated to be -
7. TESTIM
Testim is a brand drug owned by Endo Operations Ltd. It is Used for testosterone replacement therapy. Testim's 9 out of 10 patents have already expired. The remaining 1 active patent is -
1. US7320968 patent titled as " Pharmaceutical composition " took almost 3 years to get granted. It has 85 family members and is forward cited by 28 patents. This patent has never blocked any other patent application. There have been no PTAB proceedings filed against this patent. This patent has remaining life of approximately 0 years and 5 months.
Based on the patent analysis, the drug's overall patent strength is calculated to be -
8. CHILDREN'S ALLEGRA ALLERGY
Children's Allegra Allergy is a brand drug owned by Chattem Inc Dba Sanofi Consumer Healthcare. It is used for relieving symptoms associated with respiratory allergies and hives in adults and children. Children's Allegra Allergy's 9 out of 10 patents have already expired. The remaining 1 active patent is -
1. US8933097 patent titled as " Fexofenadine suspension formulation " took more than 6 years to get granted. It has 51 family members and is forward cited by 12 patents. This patent has never blocked any other patent application. There have been no PTAB proceedings filed against this patent. This patent has remaining life of approximately 5 years and 12 months.
Based on the patent analysis, the drug's overall patent strength is calculated to be -
9. CHILDREN'S ALLEGRA HIVES
Children's Allegra Hives is a brand drug owned by Chattem Inc Dba Sanofi Consumer Healthcare. It is used for treating respiratory allergies, hives (urticaria), and their associated symptoms in adults and children. Children's Allegra Hives's 9 out of 10 patents have already expired. The remaining 1 active patent is -
1. US8933097 patent titled as " Fexofenadine suspension formulation " took more than 6 years to get granted. It has 51 family members and is forward cited by 12 patents. This patent has never blocked any other patent application. There have been no PTAB proceedings filed against this patent. This patent has remaining life of approximately 5 years and 12 months.
Based on the patent analysis, the drug's overall patent strength is calculated to be -